Jeffrey Bornstein - Eledon Pharmaceuticals Chief Officer
| ELDN Stock | USD 4.26 0.01 0.24% |
Insider
Jeffrey Bornstein is Chief Officer of Eledon Pharmaceuticals
| Address | 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 |
| Phone | (949) 238-8090 |
| Web | https://eledon.com |
Eledon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3336) % which means that it has lost $0.3336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2536) %, meaning that it created substantial loss on money invested by shareholders. Eledon Pharmaceuticals' management efficiency ratios could be used to measure how well Eledon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Eledon Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 28th of November 2024, Non Currrent Assets Other is likely to grow to about 309.2 K, while Total Assets are likely to drop about 81.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| MA MS | Inozyme Pharma | N/A | |
| Marine Popoff | Hookipa Pharma | N/A | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| MSc MBA | Inozyme Pharma | 52 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Alexandra HughesWilson | Mereo BioPharma Group | 53 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.33 |
Eledon Pharmaceuticals Leadership Team
Elected by the shareholders, the Eledon Pharmaceuticals' board of directors comprises two types of representatives: Eledon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eledon. The board's role is to monitor Eledon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eledon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eledon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Perrin, Chief President | ||
| Gregory Flesher, Consultant | ||
| Bryan JD, Corporate Counsel | ||
| John Herberger, Vice Operations | ||
| Paul Little, Chief Officer | ||
| David Hovland, Chief Officer | ||
| FACS FACS, Chief Officer | ||
| Jeffrey Bornstein, Chief Officer |
Eledon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eledon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 176.8 M | ||||
| Shares Outstanding | 59.74 M | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 42.88 % | ||||
| Number Of Shares Shorted | 731.49 K | ||||
| Price To Book | 3.34 X | ||||
| EBITDA | (42.63 M) | ||||
| Net Income | (40.33 M) |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eledon Stock
| 0.77 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Eledon Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.81 | PEPG | PepGen | PairCorr |
| 0.74 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.63 | FDMT | 4D Molecular Therapeutics | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.